Ptpn11 Is A Novel Anti-Fibrotic Gene In Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Tzouvelekis, A. [1 ,2 ]
Cardenas, C. Lacks Lino [2 ]
Yu, G. [1 ]
Sakamoto, K. [1 ]
DeIuliis, J. [1 ]
Wyllie, A. [3 ]
Ahangari, F. [1 ]
Woolard, T. [1 ]
Heather, L. [1 ]
Herazo-Maya, J. D. [1 ]
Kaminski, N. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Yale Univ, New Haven, CT USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2356
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Katy M. Roach
    Amanda Sutcliffe
    Laura Matthews
    Gill Elliott
    Chris Newby
    Yassine Amrani
    Peter Bradding
    Scientific Reports, 8
  • [22] Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
    Moor, Catharina
    Kimman, Merel L.
    van Manen, Mirjam J. G.
    Dirksen, Carmen D.
    Wijsenbeek, Marlies S.
    Van Jaarsveld, F. Xana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] Pro-fibrotic Factors as Potential Biomarkers of Anti-fibrotic Drug Therapy in Patients With Idiopathic Pulmonary Fibrosis
    Lopez-Lopez, Lidia
    Cesar, Eva Cabrera
    Lara, Estrella
    Juan, M. Victoria Hidalgo-San
    Parrado, Concepcion
    Martin-Montanez, Elisa
    Garcia-Fernandez, Maria
    ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (03): : 231 - 233
  • [24] GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
    Speca, Silvia
    Dubuquoy, Caroline
    Rousseaux, Christel
    Jadot, Elodie
    Desreumaux, Pierre
    Spagnolo, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [25] Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function
    Ebina, M.
    Kimura, Y.
    Ohta, H.
    Hisata, S.
    Tamada, T.
    Nukiwa, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [26] A Description Of Anti-Fibrotic Therapy Prescribing Preferences Amongst Pulmonary Practitioners For The Management Of Idiopathic Pulmonary Fibrosis
    Jablonski, R.
    Frogameni, A.
    Brown, K. K.
    Kamangar, N.
    Murgu, S.
    Raparia, K.
    Ryu, J.
    Raoof, S.
    Suh, R. D.
    Edell, E. S.
    Kamp, D. W.
    Raj, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [27] Real-world study evaluating anti-fibrotic therapy on survival in idiopathic pulmonary fibrosis
    Robertson, Lucy
    Barnes, Joshua
    Rogers, Kirstie
    Thillai, Muhunthan
    Parfrey, Helen
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [28] Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis
    Sugino, Keishi
    Shimizu, Hiroshige
    Nakamura, Yasuhiko
    Isshiki, Takuma
    Matsumoto, Keiko
    Homma, Sakae
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 899 - 908
  • [29] Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Yoshikawa, Takumi
    Otsuka, Mitsuo
    Chiba, Hirofumi
    Ikeda, Kimiyuki
    Mori, Yuki
    Umeda, Yasuaki
    Nishikiori, Hirotaka
    Kuronuma, Koji
    Takahashi, Hiroki
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [30] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
12345